# Abemaciclib in Newly Diagnosed Meningioma Patients

> **NCT05940493** · PHASE2 · RECRUITING · sponsor: **Nader Sanai** · enrollment: 72 (estimated)

## Conditions studied

- Meningioma

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05940493
- **Lead sponsor:** Nader Sanai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-24
- **Primary completion:** 2028-09
- **Final completion:** 2030-09
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05940493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05940493, "Abemaciclib in Newly Diagnosed Meningioma Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05940493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*